The Integration of PARP Inhibition Into the Advanced Ovarian Cancer Clinical Pathway
WebcastFaculty
OVERVIEW
The Integration of PARP Inhibition Into the Advanced Ovarian Cancer Clinical Pathway is organized by PRIME Oncology and will be held during Oct 18, 2017 - Oct 18, 2018.
The target audience for this medical event is designed for gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.
Course Description :
Hear from the experts about the optimal use of PARP inhibitors (PARPi) in ovarian cancer, including optimal treatment setting, the role of biomarkers, management of adverse events, and maintenance of quality of life. This interactive case presentation will provide you with information on evidence-based treatment strategies and enable you to apply this information to patient scenarios.
Topics:
• Management of patients receiving PARPi therapy for ovarian cancer
• Adverse event management for patients receiving PARPi therapy
Conference Objectives are :
• Describe factors that impact treatment decision-making throughout the course of advanced ovarian cancer
• Define platinum sensitivity according to current guidelines
• Assess the role of germline and somatic BRCA testing and other biomarkers of genomic instability
• Evaluate the role of PARP inhibitors as maintenance therapy for relapsed platinum-sensitive disease
• Identify current and emerging settings in the clinical course of the disease for the use of PARP inhibitors
• Identify adverse events associated with PARP inhibitors, and select appropriate strategies to help ensure patient treatment adherence and optimum quality of life
Additional details will be posted as soon as they are available.
The target audience for this medical event is designed for gynecologic oncologists, medical oncologists, and other healthcare providers involved in the management of patients with advanced ovarian cancer.
Course Description :
Hear from the experts about the optimal use of PARP inhibitors (PARPi) in ovarian cancer, including optimal treatment setting, the role of biomarkers, management of adverse events, and maintenance of quality of life. This interactive case presentation will provide you with information on evidence-based treatment strategies and enable you to apply this information to patient scenarios.
Topics:
• Management of patients receiving PARPi therapy for ovarian cancer
• Adverse event management for patients receiving PARPi therapy
Conference Objectives are :
• Describe factors that impact treatment decision-making throughout the course of advanced ovarian cancer
• Define platinum sensitivity according to current guidelines
• Assess the role of germline and somatic BRCA testing and other biomarkers of genomic instability
• Evaluate the role of PARP inhibitors as maintenance therapy for relapsed platinum-sensitive disease
• Identify current and emerging settings in the clinical course of the disease for the use of PARP inhibitors
• Identify adverse events associated with PARP inhibitors, and select appropriate strategies to help ensure patient treatment adherence and optimum quality of life
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links